Pancreatic Cancer Pill Nearly Doubles Survival in Global Trial

A new oral therapy for pancreatic cancer has delivered the most significant survival improvement in decades, nearly doubling life expectancy for patients with metastatic disease who had exhausted standard options. The drug, daraxonrasib, precisely inhibits a mutated RAS protein that drives tumour growth in more than 90 per cent of cases, according to findings presented at the American Society of Clinical Oncology’s 2026 annual meeting in Chicago. In the phase 3 RASolute 302 trial, involving 500 patients randomly assigned to the experimental pill or further chemotherapy, median overall survival stretched from just over six months to beyond 13 months, with markedly fewer severe side effects. Oncologists across continents immediately described the data as a breakthrough for one of oncology’s most recalcitrant cancers.

Viewed from Los Angeles, where the study was led, the results represent “a very large step forward,” said Zev Wainberg of UCLA, though he cautioned that the drug does not yet offer a cure. In Umeå, Sweden, oncologist Daniel Öhlund welcomed an agent that for the first time proves more effective than chemotherapy for broad groups of pancreatic cancer patients—a disease that kills roughly half a million people globally each year and has seen only incremental therapeutic gains. European physicians, including those at Villejuif’s Paul-Brousse hospital near Paris, have already witnessed dramatic individual responses: Véronique, a 56-year-old metastatic patient almost out of options, described receiving the drug as “winning the lottery” after her tumours began to regress.

The RAS family of proteins, notoriously difficult to target despite their central role in oncogenesis, has long frustrated drug developers. Daraxonrasib works by locking a specific KRAS mutation into an inactive state, thereby halting the aberrant signalling that fuels pancreatic tumours. The trial enrolled patients whose disease had progressed on prior chemotherapy, a setting with few meaningful salvage therapies. Researchers at ASCO 2026 noted that the survival benefit was consistent across subgroups, though they emphasised that the pill is not a curative treatment. Regulatory submissions are expected to follow rapidly in the United States and Europe.

From São Paulo to Stockholm, analysis of the data points to a potential paradigm shift. While earlier targeted therapies often benefited only small genetic subsets, the prevalence of RAS mutations in pancreatic cancer means daraxonrasib could become a backbone of treatment for the majority of patients. Analysts in London caution that cost and access will present hurdles, particularly for health systems in low- and middle-income countries where pancreatic cancer is on the rise. Nevertheless, the trial’s clean safety profile—fewer toxicities than chemotherapy—raises hope that the drug may eventually be combined with immunotherapies or other novel agents to extend benefits further. For a disease where most patients are diagnosed late and survive less than a year, daraxonrasib has injected a rare note of optimism.